Kymera Therapeutics (KYMR) total liabilities

Total liabilities · fiscal 2025
$163.15M

Kymera Therapeutics (KYMR) had total liabilities of $163.15M at the end of fiscal 2025 (December 31, 2025). That is 14.6% higher than the $142.42M of fiscal 2024. Figures as of 18 Nov 2026, 23:47 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$163.15M
Change on fiscal 2024
+14.6%
Growth, 5 years
−4.3% a year
Highest on record
$203.29Mfiscal 2020
Lowest on record
$82.03Mfiscal 2019
Fiscal years on record
72019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Kymera Therapeutics total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities shrank at a compound 4.3% a year. Across the 7 fiscal years on record (2019–2025), the highest was $203.29M in fiscal 2020 and the lowest $82.03M in fiscal 2019.

History · 7 fiscal years

Total liabilities by fiscal year

Kymera Therapeutics total liabilities, year by year

Kymera Therapeutics (KYMR) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$163.15M 14.6% up
2024$142.42M 21.2% down
2023$180.79M 60.0% up
2022$112.98M 22.8% down
2021$146.27M 28.0% down
2020$203.29M 147.8% up
2019$82.03M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of Kymera Therapeutics and comparable companies
CompanyTotal liabilitiesFiscal year
Fresenius Medical Care FMS€16.72B2025
Kymera Therapeutics KYMR$163.15M2025
DaVita DVA$16.32B2025
Halozyme Therapeutics HALO$2.48B2025
Universal Health Services UHS$8.12B2025
Repligen RGEN$843.57M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KYMR

Kymera Therapeutics, figure by figure

Kymera Therapeutics (KYMR) overview: price, valuation and scorecardAll health care companies by market value

Kymera Therapeutics total liabilities: questions and answers

How large are Kymera Therapeutics's total liabilities?

Kymera Therapeutics (KYMR) had total liabilities of $163.15M at the end of fiscal 2025 (December 31, 2025). That is 14.6% higher than the $142.42M of fiscal 2024.

What is the growth rate of Kymera Therapeutics's total liabilities?

Over the five fiscal years to 2025 total liabilities shrank at a compound 4.3% a year.

What are the highest and lowest total liabilities figures on record for Kymera Therapeutics?

Across the 7 fiscal years on record (2019–2025), the highest was $203.29M in fiscal 2020 and the lowest $82.03M in fiscal 2019.

How is Kymera Therapeutics's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For Kymera Therapeutics it is on record here for 7 fiscal years, 2019 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Kymera Therapeutics (KYMR) total liabilities”, data as of 18 November 2026. https://funkfolio.com/stock/KYMR/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.